Acute Porphyria Drugs

Acute Porphyria Drug Database

G04CA02 - Tamsulosin
Propably not porphyrinogenic
PNP
Rationale
Tamsulosin is not suspected to be an inducer or a mechanism-based inhibitor of CYP enzymes, and is not observed to alter the metabolism of other CYP metabolized drugs.
Chemical description
Alpha1-adrenoceptor antagonist, sulphamoyl phenethylamine derivative
Therapeutic characteristics
Tamsulosin is indicated for lower urinary tract symptoms associated with benign prostate hyperplasia. It is administered orally.
Hepatic exposure
The maximal plasma concentration of tamsulosin is about 16 ng/ml, which is equivalent to 40 nM (Franco-Salinas 2010).
Metabolism and pharmakokinetics
Tamsulosin is metabolized by CYP3A4 and CYP2D6 (Kamimura 1998). Tamsulosin has not been found to be an inhibitor of CYP1A2 (Miyazawa 2002), CYP2C9 (Rolan 2003), or CYP2D6 and CYP3A4 (Modi 2008). In the literature tamsulosin is not reported to be an inducer or inhibitor of any of the quantitatively major CYP enzymes and the absence of such characteristics is also in accordance with review-papers (FDA, Hisaka 2010, Isoherranen 2009 and Pelkonen 2008). No drug-drug interaction with tamsulosin as a perpetrator has been reported in the literature.
IPNet drug reports
Uneventful use reported in 7 patients with acute porphyria.

References

  1. Scientific articles
  2. Franco-Salinas G1, de la Rosette JJ, et al. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet. 2010 Mar;49(3):177-88. #1566
  3. Hisaka, A., Y. Ohno, et al. (2010). "Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information." Pharmacol Ther 125(2): 230-248. #1567
  4. Isoherranen, N., H. Hachad, et al. (2009). "Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database." Chem Res Toxicol 22(2): 294-298. #1568
  5. Pelkonen, O., M. Turpeinen, et al. (2008). "Inhibition and induction of human cytochrome P450 enzymes: current status." Arch Toxicol 82(10): 667-715. #1572
  6. Kamimura H, Oishi S, et al. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22. PMID 9849639. #4483
  7. Miyazawa Y, Starkey LP, et al. Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation. J Int Med Res. 2002 Jan-Feb;30(1):34-43. #1570
  8. Modi NB, Kell S, et al. Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin. J Clin Pharmacol. 2008 Dec;48(12):1438-50. PMID 18832488. #4484
  9. Rolan P, Terpstra IJ, et al. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol. Br J Clin Pharmacol. 2003 Mar;55(3):314-6. PMID 12630984. #4485
  10. Government bodies
  11. #1302
  12. Drug interaction databases
  13. U.S.FoodandDrugAdministration (FDA). (27.10.2014). "Drug Developement and Drug Interactions: Table of Substrates, Inhibitors and Inducers." Retrieved 09.03.2015, from #1574
Similar drugs
Explore alternative drugs in similar therapeutic classes G04C / G04CA or go back.
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙